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Abstract 
Background and aims: The aim of this work was to compared the effect of lipid 
lowering drugs among FH subjects with a functional mutation in LDLR (LDLR FH) and 
FH with the p.(Leu167del) mutation in APOE. 
Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on 
lipid-lowering treatment (n=22) attending the Lipid Unit at the Hospital Miguel Servet. 
Age and sex matched LDLR FH from the same Unit were randomly selected as a control 
group (n=44). 
Results: The mean percentage reduction in LDLc was significantly higher in the 
p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on 
high intensity statins. Similar differences between groups were observed in non-HDLc -
49.4 % and -36.4%, respectively (p = 0.030). 
Conclusions:Subjects with p.(Leu167del) mutation have a higher lipid-lowering 
response to statins with or without ezetimibe than LDLR FH. This supports the use of 
genetics for a more efficient management of FH. 
Introduction 
Autosomal dominant hypercholesterolemias (ADH) are monogenic disorders of lipid 
metabolism characterized by high plasma levels of low-density lipoprotein (LDL) 
cholesterol, vertical transmission of the hyperlipidemic phenotype within the family and 
high risk of premature cardiovascular disease (CVD) [1]. Lipid-lowering treatment, 
usually potent statins or combination treatment, is required to obtain the recommended 
(LDL) cholesterol goals in most affected subjects [2].  
The most common gene responsible for ADH is the LDLR gene, coding for the 
LDL receptor and causing the disorder of familial hypercholesterolemia (FH) (OMIM: 
#143890). Two other genes, APOB and PCSK9, have also been found to cause a similar 
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FH phenotype [3]. ADH are in most cases responsible for the clinical diagnosis of FH. 
However, in up to 20-30% of FH cases, a causative mutation in candidate genes is not 
found, and they probably have a polygenic nature [4], and should not be considered 
ADH in spite of some familial aggregation [5]. 
Our group and other authors have recently described a new cause of ADH, the 
p.(Leu167del) mutation in the APOE gene [6–8]. This codon deletion, formerly called ∆ 
L149, is a 3-bp inframe deletion that results in the loss of a leucine at position 167 of 
the receptor-binding region of apolipoprotein E (apo E), which produces a phenotype 
indistinguishable from classical FH [6–8]. However, the mechanism of 
hypercholesterolemia in p.(Leu167del) mutation carriers is different from that in FH. 
Functional mutations in LDLR, APOB and PCSK9 genes induce FH by reducing LDL 
receptor expression or functionality at the cellular surface or interfering with the 
recognition of the LDL particles by the LDL receptor [9]. The mechanism by which the 
p.(Leu167del) mutation in APOE gene is associated with FH appears to be different. 
The in vitro cultured cell studies demonstrate that very low-density lipoprotein (VLDL) 
particles carrying apo E with the p.(Leu167del) mutation have a higher uptake by 
HepG2 and by THP-1 cells and, subsequently, LDL receptor expression is down-
regulated. The decrease of LDL receptor expression at surface membrane of hepatocytes 
would result in a decrease in LDL internalization, an increase in LDL particles 
circulating in plasma and therefore an increase in LDL cholesterol levels [10]. Since 
VLDL contains multiple copies of apo E, this gain-of-function APOE mutation binds to 
the LDL receptors with higher affinity than LDL, which contains only one copy of apo 
B [10]. 
Potent statins are the most recommended treatment for adults with FH [2,11]. 
The effect of statins has been very well demonstrated in heterozygous subjects with 
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mutations in LDLR, APOB and PCSK9 [12,13]. However, whether the lipid-lowering 
response is similar in subjects with the p.(Leu167del) mutation in APOE is still 
unknown. The different mechanism of LDL cholesterol production could also be 
associated with a different treatment response. In this retrospective case-control study, 
we have identified all carriers of the p.(Leu167del) mutation under treatment and we 
have compared the lipid lowering effects with respect to FH in subjects with a 
functional mutation in the LDLR gene. 
 
2. Materials and methods 
2.1 Subjects  
2.1.1 APOE p.(Leu167del) carriers 
All adult patients with the p.(Leu167del) mutation on lipid-lowering treatment (n=22) 
attending the Lipid Unit at the Hospital Universitario Miguel Servet, Zaragoza, Spain 
were retrospectively studied. We routinely screen for this mutation in all patients 
attending our Unit with a clinical diagnosis of primary hyperlipidemia.  
2.1.2 LDLR heterozygous carriers 
Age and sex matched subjects with genetically defined heterozygous FH from the same 
Unit were randomly selected as control group (n=44). Two controls were selected for 
each case. All controls were heterozygous carriers of a functional mutation in LDLR and 
were attending in the same period frame than cases.  
2.2 Biochemical analysis 
Ethylenediaminetetraacetic acid plasma and serum samples were collected from all 
participants after at least 10 hours of fasting, after 6 weeks without lipid-lowering drugs, 
to obtain baseline biochemical characteristics. Annual subsequent lipid analysis with 
lipid lowering drugs was recorded. In case that a subject had two or more lipid results in 
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the same year, the last one of that same year was used. Total cholesterol and triglyceride 
levels were determined by standard enzymatic methods. High-density lipoprotein 
cholesterol was measured directly by an enzymatic reaction using cholesterol oxidase 
(UniCel DxC 800; Beckman Coulter Inc., Brea, California, United States). 
Lipoprotein(a) (Lp(a)), apo A1, apo B, and C-reactive protein (CRP) were determined 
by IMMAGE kinetic nephelometry (Beckman Coulter Inc.). LDL cholesterol was 
calculated using the Friedewald’s formula. 
2.3 Genetic diagnosis 
DNA was isolated from EDTA blood samples following standard protocols. LDLR, 
APOB and PCSK9 genes were analyzed for functional mutations with Lipochip® 
platform (Progenika Grifols, Spain) [14]. Exon 4 of the APOE gene was sequenced in 
all participants, as previously described [15]. 
2.4 Follow-up 
All patients underwent checkups 1 or 2 times a year. Throughout the study, 
hypercholesterolemia was treated in accordance with the recommendations of the 
International Panel on Management of FH [16], which established the therapeutic target 
as a reduction in LDL cholesterol and/or non– high-density lipoprotein cholesterol 
(non–HDL cholesterol), according to risk factors. Since November 2013, the therapeutic 
target for patients with CVD or diabetes has been amended to LDL cholesterol < 70 
mg/dL. All participants received checkups through a face-to-face interview [17]. Statin 
use was adjusted to equivalents of rosuvastatin [11]. All participants gave written 
consent before participating in the protocol, which was approved by the Clinical 
Research Ethics Committee of Aragón, Spain. 
2.5 Statistical analyses 
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Analyses were performed using SPSS version 20.0 (Chicago, Illinois, United States). 
The nominal level for significance was p <0.05. Normal distribution of variables was 
analyzed with the Kolmogorov–Smirnov test. Numerical variables with normal 
distribution are expressed as mean ± standard deviation and those with skewed 
distribution are expressed as median [percentile 25-percentile 75]. We used Student’s t 
or Mann-Whitney tests to assess differences among two categories quantitative 
variables while Chi-squared or Fisher tests were used for categorical variables as 
appropriate.  
 
3. Results 
A total of 66 subjects, 22 carriers of the p.(Leu167del) mutation in APOE gene and 44 
heterozygous FH carriers of an LDLR functional mutation (LDLR FH) were included in 
the study. Most of the clinical, anthropometric and lipid baseline characteristics did not 
differ between groups (Table 1). Mean age was 43 years in both groups. The 
distribution of APOE common polymorphisms between cases and controls did not differ 
either. However, all p.(Leu167del) carriers were ε3/ε3, thus this codon deletion in 
APOE was in linkage disequilibrium with the ε3 allele. The p.(Leu167del) carriers 
presented triglycerides and CRP concentrations significantly higher than LDLR FH, (p 
<0.001, and p <0.03, respectively). Lp(a) was significantly lower in p.(Leu167del) 
carriers (p = 0.002). The rest of the clinical and biochemical parameters did not differ 
between the two groups (Table 1). 
Mean follow-up under lipid-lowering drugs was 4 years in p.(Leu167del) 
carriers and 3 years in LDLR FH, without differences regarding treatment time between 
groups (p = 0.330). Table 2 describes lipid values at the last visit during follow-up. 
Lipid parameters substantially improved at this visit. All subjects were on stable dose of 
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statin with or without ezetimibe at follow-up for at least 3 months. They did not differ in 
any biochemical characteristic including lipid parameters between p.(Leu167del) 
carriers and LDLR FH subjects at the final visit. Both groups obtained substantial 
reductions in their lipid values without differences between groups. However, the 
p.(Leu167del) carriers obtain similar LDL cholesterol reductions in spite of 
significantly lower dose of statins and lower use of ezetimibe than LDLR FH (p = 0.044 
and p = 0.022, respectively) (Table 2). 
The lipid-lowering effect of the different statins with or without ezetimibe 
showed important differences between groups. For this analysis, all annual lipid results 
under different treatments were used, with only one analysis per treatment per subject. 
Because only two subjects, both p.(Leu167del) carriers, were on low intensity statins, 
low and moderate intensity statin groups were put together in a single group. A total of 
36 results with low/moderate intensity statins, 28 results with high intensity statins and 
30 results with combination of high intensity statins and ezetimibe were analyzed 
(Supplemental table 1). 
The mean percentage reduction in LDL cholesterol was significantly higher in 
the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on 
high intensity statins. Similar differences between groups were observed in non-HDL 
cholesterol -49.4 % and -36.4%, respectively (p = 0.030). We also observed an 
important significative reduction in triglycerides between groups in patients with 
low/moderate and high intensity statins (Fig.1). There were not differences in weight, 
total cholesterol, HDL cholesterol and apo A1 between groups with any treatment group 
(Supplementary Table 1). To be able to rule out the difference effect is not due to the 
well-known non-lineal dose response association, we have compared the lipid lowering 
effect with the same simvastatin and rosuvastatin dose in the p.(Leu167del) carriers and 
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LDLR FH. The mean percentage reduction in non-HDL cholesterol was significantly 
higher in the p.(Leu167del) carriers (-52.7%) than in the LDLR FH (-34.1%) (p = 
0.048) when on simvastatin 40 mg/dL. Similar differences were observed in 
triglycerides -43.2 % and -6.63 %, respectively (p = 0.016).  
 
4. Discussion 
This study analyzes for the first time the effect of lipid-lowering treatment in subjects 
with the p.(Leu167del) mutation in APOE and shows a different effect with respect to a 
heterozygous FH population with a functional mutation in LDLR. We have analyzed the 
lipid-lowering response of a treatment based on statins, with or without ezetimibe, the 
most recommended drug treatment in these subjects [2,11]. The p.(Leu167del) mutation 
in APOE represents the fourth cause of FH together with functional mutations in LDLR, 
APOB and PCSK9 genes. In our population, it is the cause of approximately 3% of 
clinically defined FH in whom LDLR, APOB, and PCSK9 mutations were not found 
[10].  This prevalence of mutation carriers, although much lower than LDLR mutations, 
is higher than that observed for the PCSK9 mutation causing FH, and similar to the 
APOB mutations [14]. 
The therapeutic response in this form of FH shows that these subjects have a 
lipid-lowering response higher than that observed in the most common FH population 
with functional mutation in LDLR, with an average lowering response in LDL 
cholesterol 12.4% higher. Consequently, FH carriers of the p.(Leu167del) mutation 
would needed lower doses of statins for LDL cholesterol control than LDLR FH. 
Interestingly, p.(Leu167del) carriers have higher TG baseline and more intense lipid-
lowering drugs response for LDL cholesterol and TG. The more likely explanation of 
this mechanism is that there is a hypercatabolism of the small and medium VLDL 
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without modifying or decreasing the catabolism of large VLDL. Actually, apo E has an 
important lipolytic effect [18] that could be modified in p.(Leu167del) carriers. In 
addition, statins have key activities involved in apo E-dependent VLDL metabolism, 
which could be involved in the greater response to treatment [19]. On the other hand, 
p.(Leu167del) carriers have lower Lp(a) baseline. It has been demonstrated that APOE 
genotype has a strong influence on Lp(a) levels [20]. The p.(Leu167del) mutation seems 
to stimulate the Lpa particle clarification, which indicates this gain of function mutation 
is not limited to VLDL and remnants.  
Several important considerations can be drawn from our work. First, it points out 
the importance of the APOE gene in the therapeutic response to statins. It is well known 
and confirmed by several studies and meta-analysis that part of the interindividual 
variability found in response to statins is explained by the APOE genotype. In this way, 
subjects carrying the APOE ε4 allele obtain lower and carriers of the ε2 alleles obtain 
greater LDL cholesterol reductions with statins in comparison with the ε3 carriers [21]. 
The mechanism of this difference is not well established but it has been speculated that 
APOE genotypes affect lipid-lowering response because of the differences in binding of 
apo E isoforms to lipoprotein receptors [22]. We speculate that the higher lipid-lowering 
response in p.(Leu167del) carriers is due to the fact that this mutant APOE has a 
markedly increased binding affinity as compared with apo E3, and statin treatment 
reduces the synthesis of VLDL particles and increase the uptake of LDL by increasing 
the expression of receptors [23], hence reducing circulating lipoproteins. Subjects with 
the p.(Leu167del) mutation have normal LDLR and APOB alleles, so an increase in 
LDL receptors would have a greater impact than in LDLR FH patients. In addition, the 
reduction of VLDL particle synthesis with statins could have a greater effect on subjects 
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with the p.(Leu167del) mutation. The reduction of triglycerides is more intense in FH 
subjects with p.(Leu167del) mutation than with functional mutations in LDLR. 
Secondly, our results provide another argument for the indication of genetic 
studies in familial hypercholesterolemia. The knowledge of the genetic bases does not 
only confirm the diagnosis and facilitates the identification of affected relatives, but it 
could modulate treatment. The European and American guidelines [2,11] indicate high 
doses of high potency statins in suspected genetic hypercholesterolemia with LDL 
cholesterol values >190 mg/dL. Our results would support that in the presence of the 
p.(Leu167del) mutation, a less intensive treatment from the beginning and escalating 
doses according to response could be reasonable, since the patients obtain a mean 50% 
reduction in LDL cholesterol with moderate intensity statins. 
Our study has some limitations: it is a retrospective study and not all subjects 
had the same statin treatment. On the other hand, the number of subjects recruited in 
this study is not very high, however, subjects with p.(Leu167del) mutation are 
approximately only 3% of clinically defined FH without mutations in candidate genes, 
which limits the availability of thesubjects. To overcome this limitation, two LDLR FH 
were selected for each case matched by sex and age, which increased the statistical 
power of the study.  
In summary, subjects with p.(Leu167del) mutation, a rare form of FH, seem to 
have a higher lipid-lowering response to statins with or without ezetimibe than FH 
subjects with a functional mutation in LDLR. Our results postulate the importance of 
APOE in response to statins, the different effect of statins depends on the mechanism of 
production of dyslipidemia, and indicates the use of genetics tools for a more efficient 
management of subjects with FH. New studies along this line are mandatory to clarify 
the results on APOE in lipids metabolism. 
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Fig. 1. Variation (%) in LDL cholesterol, non-HDL cholesterol, triglycerides and 
apolipoprotein B in p.(Leu167del) mutation carriers and heterozygous FH subjects with 
mutation in LDLR divided by lipid-lowering treatment intensity. 
Quantitative variables with normal distribution are expressed as mean ± standard deviation. 
The p value was calculated by Student's t test. 
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 Table 1. Baseline clinical and biochemical characteristics of study subjects with the APOE 
p.(Leu167del) mutation and matched FH with LDLR functional mutation. 
Variable p.(Leu167del) FH 
n = 22 
LDLR FH 
n = 44 p 
Age, years 43.0 ± 14.1 43.0 ±14.3 0.942 
Men, n (%) 9 (40.9) 18 (40.9) 1.000 
Smoker, n (%) 5 (22.7) 11 (25.0) 
0.943 Non smoker, n (%) 12 (54.5) 21 (47.7) 
Former smoker, n (%) 5 (22.7) 12 (27.3) 
Previous cardiovascular disease, % 2 (9.10) 3 (7.00) 0.754 
Type 2 diabetes, n (%) 2 (9.10) 1 (2.30) 0.256 
Hypertension, n (%) 4 (18.2) 4 (9.10) 0.425 
Corneal arcus, n (%) 8 (36.4) 20 (45.5) 0.481 
Tendon xanthoma, n (%) 0 7 (15.9) 0.086 
Body mass index, kg/m2 26.0 ± 5.07 24.3 ± 4.25 0.159 
Total cholesterol, mg/dL 345 ± 85.0 346 ± 70.1 0.959 
LDL cholesterol, mg/dL 255 ± 75.4 267 ± 65.6 0.539 
HDL cholesterol, mg/dL 62.0 ± 22.4 58.0 ± 12.8 0.422 
Non-HDL cholesterol, mg/dL 283 ± 72.4 287 ± 73.7 0.875 
Triglycerides, mg/dL 146 (119 -282) 101 (73.3 – 126) <0.001 
Apolipoprotein A1, mg/dL 284 ± 72.4 287 ± 74.0 0.074 
Apolipoprotein B, mg/dL 169 ± 31.4 154 ± 28.3 0.506 
Lipoprotein (a), mg/dL 7.41 (1.50 – 29.0) 38.0 (11.0 – 69.2) 0.002 
Glucose, mg/dL 85.0 (80.0 – 94.0) 88.0 (81.0 – 94.0) 0.543 
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C reactive protein, g/L 2.10 (1.25 – 2.90) 1.05 (0.40 – 3.00) 0.030 
APOE genotype, n (%) 
ε3/3 
 
22 (100) 31 (72.1) 
0.090 
ε3/2 
 
0 4 (9.30) 
ε3/4 0 6 (14.0) 
ε4/4 
 
0 1 (2.30) 
ε2/4 0 1 (2.30) 
 
Quantitative variables are expressed as mean ± standard deviation, except for variables not 
following the normal distribution, expressed as median (interquartile range). Qualitative variables 
are expressed as n (%). The p value was calculated by Student's t test, Mann-Whitney U and Chi - 
square as appropriate.  
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Table 2. Clinical and biochemical characteristics of study subjects with the APOE 
p.(Leu167del) mutation and matched LDLR FH at the final visit. 
Quantitative variables are expressed as mean ± standard deviation, except for variables not 
following the normal distribution, expressed as median (interquartile range). Qualitative 
variables are expressed as %. The p value was calculated by Student's t test, Mann-Whitney 
U and Chi - square as appropriate. 
 
Variable p.(Leu167del) carriers 
n= 22 
LDLR FH 
n= 44 p 
Weight, kg 74.1 ± 10.5 67.9 ± 13.1 0.119 
Total cholesterol, mg/dL 215 ± 51.8 215 ± 34.6 0.997 
LDL cholesterol, mg/dL 127 ± 39.1 137 ± 31.0 0.285 
HDL cholesterol, mg/dL 69.1 ± 20.5 59.3 ± 14.3 0.065 
Non-HDL cholesterol, mg/dL 146 ± 40.6 156 ± 33.3 0.325 
Triglycerides, mg/dL 96.1 ± 31.0 96.4 ± 37.7 0.976 
Apolipoprotein A1, mg/dL 175 ± 50.0 162 ± 33.5 0.345 
Apolipoprotein B, mg/dL 108 ± 24.0 111 ± 25.9 0.738 
Follow-up, years 4 (2.0-5.25) 3 (2.0-4.0) 0.330 
Rosuvastatin equivalent dose, mg/day 5.00 (5.00-10.0) 10.0 (5.00-20.0) 0.044 
Ezetimibe use, n (%) 7 (31.8) 27 (61.4) 0.022 
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